Polyrizon Ltd
PLRZ
Company Profile
Business description
Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. Its technology platforms are Capture & Contain and Trap & Target.
Contact
5 Ha-Tidhar Street
Raanana4366507
ISRT: +972 93740120
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,641.80 | 10.30 | 0.12% |
| CAC 40 | 7,826.79 | 1.34 | -0.02% |
| DAX 40 | 24,226.49 | 198.84 | 0.83% |
| Dow JONES (US) | 42,343.65 | 740.58 | 1.78% |
| FTSE 100 | 8,778.05 | 60.08 | 0.69% |
| HKSE | 23,276.60 | 105.39 | -0.45% |
| NASDAQ | 19,199.16 | 461.96 | 2.47% |
| Nikkei 225 | 37,918.86 | 194.75 | 0.52% |
| NZX 50 Index | 12,379.59 | 202.74 | -1.61% |
| S&P 500 | 5,921.54 | 118.72 | 2.05% |
| S&P/ASX 200 | 8,411.20 | 3.60 | 0.04% |
| SSE Composite Index | 3,341.78 | 1.09 | 0.03% |